Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03574597 · ClinicalTrials.gov registry record · Phase 3
Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 17,604
- Enrollment target
NCT03574597 is a Phase 3 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 17,604 participants.
The verdict
NCT03574597, a Phase 3 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 17,604 participants
- Enrollment target
Study Summary
The researchers are doing the study to see if semaglutide may reduce the risk of having cardiovascular events in patients with overweight or obesity and with prior cardiovascular disease. The participant will either get semaglutide (active medicine) or placebo ("dummy" medicine). Which treatment the participants get is decided by chance. The participant's chance of getting semaglutide or placebo is the same. The participant will get the study medicine in a pen. The participants will need to use the pen to inject the study medicine in a skinfold once a week. The study will last for about 2.5 to 5 years. Participants will have up to 25 clinic visits with the study doctor.
Interventions
- DRUG Semaglutide
- DRUG Placebo (semaglutide)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17,604 participants |
| Start Date | 2018-10-24 |
| Est. Completion | 2023-06-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03574597
The ClinicalTrials.gov registry entry for NCT03574597 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 17,604 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Semaglutide is the first listed.
NCT03574597 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03574597 about?
NCT03574597 is a clinical study titled "Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity". The researchers are doing the study to see if semaglutide may reduce the risk of having cardiovascular events in patients with overweight or obesity and with prior cardiovascular disease. The participant will either get semaglutide (active medicine) or placebo ("dummy" medicine). Which treatment the...
What is the current status of trial NCT03574597?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 17,604 participants. The study started on 2018-10-24. Estimated completion is 2023-06-29.
What interventions are being tested in trial NCT03574597?
The interventions under investigation include: Semaglutide (DRUG), Placebo (semaglutide) (DRUG).
Who is sponsoring clinical trial NCT03574597?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.